Literature DB >> 23775497

Prostate specific membrane antigen produces pro-angiogenic laminin peptides downstream of matrix metalloprotease-2.

Rebecca E Conway1, Kyle Joiner, Alex Patterson, David Bourgeois, Robert Rampp, Benjamin C Hannah, Samantha McReynolds, John M Elder, Hannah Gilfilen, Linda H Shapiro.   

Abstract

Prostate specific membrane antigen (PSMA) is a pro-angiogenic cell-surface protease that we previously demonstrated regulates blood vessel formation in a laminin and integrin β1-dependent manner. Here, we examine the principal mechanism of PSMA activation of integrin β1. We show that digesting laminin sequentially with recombinant matrix metalloprotease-2 (MMP-2) and PSMA generates small peptides that enhance endothelial cell adhesion and migration in vitro. We also provide evidence that these laminin peptides activate adhesion via integrin α6β1 and focal adhesion kinase. Using an in vivo Matrigel implant assay, we show that these MMP/PSMA-derived laminin peptides also increase angiogenesis in vivo. Together, our results reveal a novel mechanism of PSMA activation of angiogenesis by processing laminin downstream of MMP-2.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23775497     DOI: 10.1007/s10456-013-9360-y

Source DB:  PubMed          Journal:  Angiogenesis        ISSN: 0969-6970            Impact factor:   9.596


  18 in total

1.  Maternal inflammation leads to impaired glutamate homeostasis and up-regulation of glutamate carboxypeptidase II in activated microglia in the fetal/newborn rabbit brain.

Authors:  Zhi Zhang; Bassam Bassam; Ajit G Thomas; Monica Williams; Jinhuan Liu; Elizabeth Nance; Camilo Rojas; Barbara S Slusher; Sujatha Kannan
Journal:  Neurobiol Dis       Date:  2016-06-17       Impact factor: 5.996

2.  PSMA redirects MAPK to PI3K-AKT signaling to promote prostate cancer progression.

Authors:  Leslie Ann Caromile; Linda H Shapiro
Journal:  Mol Cell Oncol       Date:  2017-04-28

Review 3.  Looking for Drugs in All the Wrong Places: Use of GCPII Inhibitors Outside the Brain.

Authors:  James J Vornov; Diane Peters; Mike Nedelcovych; Kristen Hollinger; Rana Rais; Barbara S Slusher
Journal:  Neurochem Res       Date:  2019-11-20       Impact factor: 3.996

Review 4.  Renal Cell Carcinoma: the Oncologist Asks, Can PSMA PET/CT Answer?

Authors:  Chiara Pozzessere; Maria Bassanelli; Anna Ceribelli; Sazan Rasul; Shuren Li; John O Prior; Francesco Cicone
Journal:  Curr Urol Rep       Date:  2019-10-11       Impact factor: 3.092

5.  The prostate-specific membrane antigen (PSMA)-targeted radiotracer 18F-DCFPyL detects tumor neovasculature in metastatic, advanced, radioiodine-refractory, differentiated thyroid cancer.

Authors:  Prasanna Santhanam; Jonathon Russell; Lisa M Rooper; Paul W Ladenson; Martin G Pomper; Steven P Rowe
Journal:  Med Oncol       Date:  2020-10-09       Impact factor: 3.064

6.  FOLH1/GCPII is elevated in IBD patients, and its inhibition ameliorates murine IBD abnormalities.

Authors:  Rana Rais; Weiwei Jiang; Huihong Zhai; Krystyna M Wozniak; Marigo Stathis; Kristen R Hollinger; Ajit G Thomas; Camilo Rojas; James J Vornov; Michael Marohn; Xuhang Li; Barbara S Slusher
Journal:  JCI Insight       Date:  2016-08-04

7.  PSMA redirects cell survival signaling from the MAPK to the PI3K-AKT pathways to promote the progression of prostate cancer.

Authors:  Leslie Ann Caromile; Kristina Dortche; M Mamunur Rahman; Christina L Grant; Christopher Stoddard; Fernando A Ferrer; Linda H Shapiro
Journal:  Sci Signal       Date:  2017-03-14       Impact factor: 8.192

8.  Hetero-bivalent agents targeting FAP and PSMA.

Authors:  Srikanth Boinapally; Alla Lisok; Gabriela Lofland; Il Minn; Yu Yan; Zirui Jiang; Min Jay Shin; Vanessa F Merino; Lei Zheng; Cory Brayton; Martin G Pomper; Sangeeta Ray Banerjee
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-08-15       Impact factor: 10.057

Review 9.  The therapeutic and diagnostic potential of the prostate specific membrane antigen/glutamate carboxypeptidase II (PSMA/GCPII) in cancer and neurological disease.

Authors:  James C Evans; Meenakshi Malhotra; John F Cryan; Caitriona M O'Driscoll
Journal:  Br J Pharmacol       Date:  2016-09-23       Impact factor: 8.739

Review 10.  Targeting PSMA by radioligands in non-prostate disease-current status and future perspectives.

Authors:  Philipp Backhaus; Benjamin Noto; Nemanja Avramovic; Lena Sophie Grubert; Sebastian Huss; Martin Bögemann; Lars Stegger; Matthias Weckesser; Michael Schäfers; Kambiz Rahbar
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-01-15       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.